"I think this research is worth half-a-billion minimum."
"It could be argued that even this number ($500 million) represents a hugely discounted price (after all, it is 83% less than the $2.8 billion Pfizer spent). The insulin market has not gone away. Generex's current market cap of $23.44 million is absurdly, ridiculously low."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.